Search

  • HOME
  • Search
Review Article
Promising role of Voxelotor in managing sickle cell disease in children: a narrative review
Amit Agrawal, Gaurav Jadon, Japna Singh, Dalwinder Janjua
Sickle cell disease (SCD) is characterized by chronic hemolytic anemia and intermittent vaso-occlusive crises. To date, four disease-modifying drugs have been approved for the treatment of SCD: hydroxyurea (an S-phase inhibitor), L-glutamine (an amino acid), crizanlizumab (a P-selectin inhibitor), and voxelotor (a hemoglobin S polymerization inhibitor). Preclinical studies suggested that voxelotor effectively treats SCD and sickle cell anemia (SCA). In...
Infection
Safety monitoring of COVID-19 vaccines: February 26, 2021, To June 4, 2022, Republic of Korea
Yeon-Kyeng Lee, Yunhyung Kwon, Yesul Heo, Eun Kyoung Kim, Seung Yun Kim, Hoon Cho, Seontae Kim, Mijeong Ko, Dosang Lim, Soon-Young Seo, Enhi Cho
Clin Exp Pediatr. 2023;66(10):415-423.   Published online June 13, 2023
· Enhanced safety monitoring system of coronavirus disease 2019 (COVID-19) vaccines were implemented to detect signals rapidly as part of the national COVID-19 vaccination program.
· As of June 4, 2023, reported adverse events after COVID-19 vaccination was 0.38% among 125,107,883 doses of COVID- 19 vaccines administered.
· Most reported adverse reactions after COVID-19 vaccinations have shown nonserious and mild intensity.
Updates on the coronavirus disease 2019 vaccine and consideration in children
Hyun Mi Kang, Eun Hwa Choi, Yae-Jean Kim
Clin Exp Pediatr. 2021;64(7):328-338.   Published online June 21, 2021
· The number of coronavirus disease 2019 cases has exponentially increased worldwide, and children ≤19 years old account for 11.0% of all confirmed cases.
· mRNA vaccines, BNT162b2 and mRNA-1273, and adenoviral vector vaccines, AZD1222 and Ad26.COV2.S, authorized for emergency use in the Emergency Use Listing of the World Health Organization are reviewed.
· Clinical trials of these vaccines have shown that they are safe and serious adverse reactions are rarely observed.
Original Article
Immunology
Immunogenicity and safety of a 12-valent pneumococcal conjugate vaccine in infants aged 6–10 weeks: a randomized double-blind active-controlled trial
Jonghoon Shin, Jamaree Teeratakulpisarn, Thanyawee Puthanakit, Tuangtip Theerawit, Ji Hwa Ryu, Jinhwan Shin, Seulgi Lee, Hayoung Lee, Kyungjun An, Hun Kim
Clin Exp Pediatr. 2020;63(7):265-271.   Published online December 6, 2019
Question: The immunogenicity and safety of GBP411 when administered to healthy infants are not understood.
Finding: The intergroup differences were not significant for all 12 serotypes after the booster dose. The overall incidence of solicited local adverse events between the groups did not differ significantly.
Meaning: GBP411 with a 2p+1 dosing schedule induced a substantial immune response, and may be safe for administration to healthy infants.
General Pediatrics
Use of child safety seats during transportation of newborns
Seon Hyuk Kim, Sung Won Park, Yeon Kyung Lee, Sun Young Ko, Son Moon Shin
Clin Exp Pediatr. 2018;61(8):253-257.   Published online August 15, 2018

Purpose: Child safety seats (CSS) are critical for the protection of children, in case of motor vehicle accidents. Although the national legislation mandates that all newborns must be placed in an appropriately installed CSS during transportation, people often do not perceive the importance of CSS and do not use it as recommended. The purpose of this survey was to understand...
Neonatology (Perinatology)
Experience and pharmacokinetics of Levetiracetam in Korean neonates with neonatal seizures
Jae Won Shin, Yun Seob Jung, Kyungsoo Park, Soon Min Lee, Ho Seon Eun, Min Soo Park, Kook In Park, Ran Namgung
Clin Exp Pediatr. 2017;60(2):50-54.   Published online February 27, 2017
Purpose

The aims of this study were to evaluate the safety and pharmacokinetics of levetiracetam (LEV) in neonates with seizures and to establish a population pharmacokinetics (PPK) model by using the software NONMEM.

Methods

A retrospective analysis of 18 neonatal patients with seizures, who were treated with LEV, including 151 serum samples, was performed. The mean loading dose was 20 mg/kg, followed by...

A prospective study to assess the efficacy and safety of oral propranolol as first-line treatment for infantile superficial hemangioma
Yeong Ju Yun, Yun Hee Gyon, Sohyoung Yang, Youn Kyung Lee, Joohyun Park, Meerim Park
Clin Exp Pediatr. 2015;58(12):484-490.   Published online December 22, 2015
Purpose

To determine the efficacy and safety of oral propranolol as a first-line treatment for superficially located infantile hemangioma (IH) and propose an assessment tool to measure treatment response.

Methods

Patients with superficial IH under 1 year of age were prospectively recruited between May 2012 and December 2013 at the Department of Pediatrics of Chungbuk National University Hospital. Propranolol was administered to 12...

Review Article
Debriefing in pediatrics
Su Jin Cho
Clin Exp Pediatr. 2015;58(2):47-51.   Published online February 28, 2015

Debriefing is a conversational session that revolves around the sharing and examining of information after a specific event has taken place. Debriefing may follow a simulated or actual experience and provides a forum for the learners to reflect on the experience and learn from their mistakes. Originating from the military and aviation industry, it is used on a daily basis...

Efficacy and safety of growth hormone treatment for children born small for gestational age
Il Tae Hwang
Clin Exp Pediatr. 2014;57(9):379-383.   Published online September 30, 2014

Recombinant growth hormone (GH) is an effective treatment for short children who are born small for gestational age (SGA). Short children born SGA who fail to demonstrate catch-up growth by 2-4 years of age are candidates for GH treatment initiated to achieve catch-up growth to a normal height in early childhood, maintain a normal height gain throughout childhood, and achieve...

Original Article
Long-term safety of PEG 4000 in children with chronic functional constipation: A biochemical perspective
Sun Hwan Bae
Clin Exp Pediatr. 2010;53(7):741-744.   Published online July 31, 2010
Purpose

To evaluate the long-term safety of polyethylene glycol (PEG) 4000 in children with constipation, particularly the biochemical aspects of safety.

Methods

Medical records were evaluated, and 100 children, who had been taking PEG 4000 for more than 6 months, and who had been under clinical and biochemical monitoring, were enrolled. Ages; 6.11±3.12 years, Duration of therapy; 16.93±7.02 months, dose of PEG 4000;...

Clinical efficacy and safety of lamotrigine monotherapy in newly diagnosed pediatric patients with epilepsy
Ji Hye Han, Jung Eun Oh, Sun Jun Kim
Clin Exp Pediatr. 2010;53(4):565-570.   Published online April 15, 2010
Purpose : To verify the efficacy and safety of lamotrigine (LTG) monotherapy in newly diagnosed children with epilepsy. Methods : We prospectively enrolled 148 children who had undergone LTG monotherapy at our institution between September 2002 and June 2009. Twenty-nine patients were excluded: 19 due to incomplete data and 10 were lost to follow up. The data of the remaining...
Montelukast as an add-on therapy in bronchopulmonary dysplasia
He Min Kim, Ji Eun Song, Soon Min Lee, Min Soo Park, Kook In Park, Ran Namgung, Chul Lee
Clin Exp Pediatr. 2009;52(2):181-186.   Published online February 15, 2009
Purpose : Inflammation plays a potential role in the pathogenesis of bronchopulmonary dysplasia (BPD). Strategies for preventing BPD include respiratory management, antioxidants, nutritional treatment, and others such as anti-inflammatory agents. We aimed to assess the safety, tolerability, and efficacy of montelukast (MK), a cysteinyl leukotriene 1 receptor antagonist, as an add-on therapy in BPD. Methods : In addition to currently available...
The immunogenicity and reactogenicity of Td booster vaccination in Korean preadolescents, aged with 11-12 years old
Soo Young Lee, Ga Young Kwak, Hye Rin Mok, Jong Hyun Kim, Jae Kyun Hur, Kyung Il Lee, Park Joon Su, Sang Hyuk Ma, Hwang Min Kim, Jin Han Kang
Clin Exp Pediatr. 2008;51(11):1185-1190.   Published online November 15, 2008
Purpose : This study was undertaken to evaluate the immunogenicity and reactogenicity of Td booster immunization in early preadolescents of Korea. Methods : Healthy preadolescents, who had been vaccinated with 4 or 5 doses of DTaP vaccines until 6 years old age, were enrolled in this study from August 2006 to April 2007. Diphtheria and tetanus anti-toxoid antibodies in sera were...
Safety and efficacy of the ultra-rush immunotherapy with extracts of Dermatophagoides pteronyssinus in children
Sei Eun Hyun, Hyoung Yun Kim, Ji Hee Kwak, Youn Ho Shin, Ji Yeong Seo, Man Yong Han
Clin Exp Pediatr. 2008;51(8):868-873.   Published online August 15, 2008
Purpose : Immunotherapy is accepted as the only treatment of allergic disease that can modify the natural course of the disease and ameliorate symptoms. This study aimed to evaluate the safety and efficacy of ultra-rush therapy using Dermatophagoides extracts in children. Methods : Of children older than four years who had visited Bundang CHA Pediatric Allergy Clinic, those showing positive...
Efficacy and safety of oxcarbazepine in epileptic children
Hye Kyung Shin, Yoon Lee, Jee-Yeon Lee, Wooksun Choi, So-Hee Eun, Baik-Lin Eun, Young Sook Hong, Joo Won Lee
Clin Exp Pediatr. 2008;51(2):162-169.   Published online February 15, 2008
Purpose : Oxcabarzepine (OXC), newly recommended antiepileptic drug, has been prescribed for patients with partial seizures and generalized tonic clonic seizures in Korea from 1999. There are limited reports about an efficacy of OXC therapy in epileptic children in Korea. This study evaluated the efficacy and safety of OXC in the light of our experience. Methods : The patients, who had...
The immunogenicity and safety of three-component DTaP vaccine in Korean infants
Jin Han Kang, Jong Hyun Kim, Jung Hyun Lee, Soo Young Lee, Young Jin Hong, Chang Hwi Kim
Clin Exp Pediatr. 2007;50(4):355-362.   Published online April 15, 2007
Purpose : We conducted the study to evaluate the immunogenicity and safety of three component DTaP vaccine (Infanrix ) in a group of Korean healthy infants on a three-dose primary vaccination. And we compared the immunogenicity of this DTaP vaccine with two component DTaP vaccine which has been widely used in Korea. Methods : We enrolled one hundred fifty one healthy...
Antibody Response and Adverse Reaction Following Immunization with MMR Vaccine Produced on Human Diploid Cells in Korean Children
Sung Hee Oh, Jin Han Kang, Young Mo Sohn, Hoan Jong Lee, Bok Yang Pyun, Chang Hwi Kim
Clin Exp Pediatr. 2000;43(4):489-495.   Published online April 15, 2000
Purpose : This prospective study was performed to evaluate the immunogenecity and safety of MMR vaccine(Triviraten Berna¢c) in Korea children. Methods : Seventy-three infants aged between 12 to 18 months were recruited from several university hospitals between December 1995 to June 1996. MMR vaccine(Triviraten Berna¢c) was administrered and blood was obtained before and 6-10 weeks after vaccination. IgG antibodies against measles,...
Safety and Immunogenicity of Live Attenuated Varicella Virus Vaccine(MAV/06 strain)
Young Mo Sohn, Chong Young Park, Kyu Kye Hwang, Gyu Jin Woo, Song Yong Park
Clin Exp Pediatr. 1994;37(10):1405-1413.   Published online October 15, 1994